Intuitive Surgical, Inc.

ISRG Healthcare Medical - Instruments & Supplies NASDAQ

Back to Search

$486.29

$-10.41 (-2.10%)

Open: $490.27 | High: $490.65 | Low: $478.26 | Prev Close: $496.70

Market Cap: $172.70B

Volume: 1.1M | Avg: 1.9M

Last updated: March 06, 2026 at 06:03 PM
Investment Rating
B+

Neutral

Overall Score: 60/100

Rating Breakdown:
DCF Score 3/5
60%
Neutral
ROE Score 4/5
80%
Buy
ROA Score 5/5
100%
Strong Buy
D/E Score 4/5
80%
Buy
P/E Score 1/5
20%
Strong Sell
P/B Score 1/5
20%
Strong Sell
Add to Watchlist Add to Portfolio
Stock Score Analysis
C

Stock Score: 626

Comprehensive Quality Assessment

Component Breakdown:
Efficiency 45
Financial Health 125
Growth 100
Market Sentiment 10
Risk 30
Lower is better
Valuation 6
Momentum 10
View Full Stock Score Dashboard
Valuation Metrics
Valuation Ratios
P/E Ratio 61.87
P/B Ratio 9.68
P/S Ratio 17.15
EPS $7.86
Beta 1.68
Shares Outstanding 355.13M
Price Range & Moving Averages
52-Week High $603.88
52-Week Low $425.00
SMA 50 $526.33
SMA 200 $513.18
Earnings
Next Earnings April 21, 2026 09:00 PM ET
Financial Ratios
Margins
Gross Margin 66.0%
Operating Margin 29.3%
Net Margin 28.4%
Returns
ROE 16.4%
ROA 13.8%
Liquidity & Leverage
Debt/Equity 0.02
Current Ratio 4.87
Quick Ratio 3.96
Balance Sheet
Total Assets $20.63B
Total Liabilities $2.69B
Total Equity $17.82B
Cash $3.37B
Total Debt $302.80M
Net Debt $-3,065,200,000
Income Statement
Revenue $10.06B
Gross Profit $6.64B
Operating Income $2.95B
Net Income $2.86B
EBITDA $3.62B
Revenue/Share $28.36
Cash Flow
Operating CF $3.03B
CapEx $539.80M
Free Cash Flow $2.49B
Book Value/Share $50.55
Tangible Book/Share $49.48
Equity/Share $50.22
Technical Indicators
RSI (14) 45.37 Neutral
MACD
-6.32 Signal: -7.87
Volatility 24.33%
Trading Signal Bullish
Performance & Returns
Total Returns
1 Year -13.41%
Risk-Adjusted Returns
Sharpe Ratio -0.61 Poor
Volatility (Ann.) 29.6% Moderate
vs S&P 500 (SPY)
ISRG (1Y) -13.41%
S&P 500 (1Y) +13.03%
Alpha (Excess Return) -26.45%
Risk-free rate: 4.5% (3-month US Treasury) • Based on 199 trading days
Sector Comparison (Healthcare)
Compared to 52 peers in Healthcare
Metric ISRG Sector Avg Percentile
P/E Ratio 61.87 27.0 94%
P/B Ratio 9.68 -19.71 89%
ROE (%) 16.39% -9.60% 64%
Net Margin (%) 28.38% 8.95% 89%
Stock Score 626 542.0 91%
1Y Return (%) -13.41 % +8.57 % 23%
Percentile: 0% = worst in sector, 100% = best in sector
📊 Historical Price Analysis (Last 200 Days)

Loading chart...

Technical Analysis
Ticker Close SMA 5 SMA 8 SMA 13 SMA 50 SMA 200 RSI (14) MACD Volatility (%) Volume Signal SMA Decision
ISRG $486.29 $495.44 $497.81 $497.80 $524.64 $512.84 45.37 -6.32 24.33% 788876 Weak Short Price Below SMAs
Candlestick Patterns

There wasn't any recognizable pattern for the ISRG stock

News Sentiment
📊 Ticker 📰 Headline 💭 Sentiment 📡 Source 🔗 URL
ISRG Why Intuitive Surgical, Inc. (ISRG) Dipped More Than Broader Market Today Neutral zacks.com Read More
ISRG Wall Street Analysts Think Intuitive Surgical (ISRG) Could Surge 29.72%: Read This Before Placing a Bet Neutral zacks.com Read More
ISRG Investors Heavily Search Intuitive Surgical, Inc. (ISRG): Here is What You Need to Know Neutral zacks.com Read More
ISRG Intuitive Surgical, Inc. (ISRG) Suffers a Larger Drop Than the General Market: Key Insights Negative zacks.com Read More
ISRG ISRG's da Vinci Gains FDA Nod for Cardiac Surgery: TAM Growth Ahead? Positive zacks.com Read More
Recent Insider Trading

No recent insider trading data available for ISRG

Company Information

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

CEO David J. Rosa
Employees 15638
Country US
IPO Date 2000-06-16
Exchange NASDAQ
Website https://www.intuitive.com
Sector Healthcare
Industry Medical - Instruments & Supplies
Similar Stocks (Healthcare - Medical - Instruments & Supplies)
BDX

Becton, Dickinson and Company

Price: $168.65
Change: -0.76%
Market Cap: $6110B
P/E: 27.60
Score: E (502)
View Details
RMD

ResMed Inc.

Price: $252.87
Change: -0.96%
Market Cap: $3691B
P/E: 25.26
Score: C (647)
View Details
WST

West Pharmaceutical Services, Inc.

Price: $245.86
Change: +0.62%
Market Cap: $1770B
P/E: 36.21
Score: D (542)
View Details
HOLX

Hologic, Inc.

Price: $75.74
Change: -0.01%
Market Cap: $1690B
P/E: 31.43
Score: C (625)
View Details
Rating Metrics Explained
DCF Score (Discounted Cash Flow)

Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.

ROE Score (Return on Equity)

Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.

ROA Score (Return on Assets)

Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.

D/E Score (Debt-to-Equity)

Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.

P/E Score (Price-to-Earnings)

Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.

P/B Score (Price-to-Book)

Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.

Rating Recommendations:

Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:

  • Strong Buy (5/5): Excellent score - strong positive indicator
    • The metric significantly outperforms industry averages (top 20% of companies)
    • Indicates exceptional financial health or attractive valuation in that category
  • Buy (4/5): Good score - positive indicator
    • Above-average performance (top 40% of companies)
    • Shows strong fundamentals with room for improvement
  • Neutral (3/5): Average score - neutral indicator
    • Performance in line with industry median (middle 20%)
    • Neither significantly positive nor negative signal
  • Sell (2/5): Below average - negative indicator
    • Below-average performance (bottom 40% of companies)
    • Suggests weakness in this particular metric
  • Strong Sell (1/5): Poor score - strong negative indicator
    • Significantly underperforms industry (bottom 20%)
    • Indicates potential risk or overvaluation in that category
Note: The overall rating combines all six component scores to provide a comprehensive investment assessment. No single metric should be used in isolation for investment decisions.